GSK1838705A
Based on 8 publication(s) in Google Scholar
GSK1838705A is a potent and reversible IGF-IR and the insulin receptor inhibitor with IC50s of 2.0 and 1.6 nM, respectively. It also inhibits ALK with an IC50 of 0.5 nM.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.58%
- CAS 番号: 1116235-97-2
- 分子式: C27H29FN8O3
- 分子量:532.57
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-10200
BMS-754807IGF-1R/IR Inhibitor -
HY-10191
LinsitinibIGF-1R/Insulin Receptor Inhibitor -
HY-12678
EntrectinibTrk/ROS1/ALK Inhibitor -
HY-15609
AZD-3463ALK/IGF1R Inhibitor -
HY-15656
CeritinibALK Inhibitor -
HY-13011
AlectinibALK Inhibitor -
HY-12215
LorlatinibALK/ROS1 Inhibitor -
HY-103022
RepotrectinibROS1/TRK/ALK Inhibitor -
HY-15897
LDN-212854ALK2 Inhibitor -
HY-10262
BMS-536924IGF-1R/IR Inhibitor -
HY-10201
SorafenibMultikinase Inhibitor -
HY-70062
PevonedistatNAE Inhibitor
MedChemExpress（MCE）の使用を引用している文献 GSK1838705A
More- Nat Commun. 2021 Jul 16;12(1):4360. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Aquaculture. 2025 Aug 15.
- ACS Chem Biol. 2017 May 19;12(5):1245-1256. [Abstract]
- Fundam Clin Pharmacol. 2020 Oct;34(5):571-580. [Abstract]
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):71-78. [Abstract]
- bioRxiv. 2023 May 14.
- Patent. US20180263995A1.
生物活性
製品説明
IC50 & Target
IC50: 2.0 nM (IGF-IR), 1.6 nM (insulin receptor), 0.5 nM (ALK)[1]
体外実験
In cellular phosphorylation assays, GSK1838705A potently inhibits IGF-IR and insulin receptor phosphorylation with IC50s of 85 and 79 nM, respectively. appKi values are 0.7 nM for IGF-IR and 1.1 nM for insulin receptor using the filter binding assay. GSK1838705A inhibits the proliferation in a panel of cell lines derived from solid and hematologic tumors. The EC50s of GSK1838705A range from 20 nM to >8 μM, but are <1 μM in most multiple myeloma and Ewing's sarcoma cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 1116235-97-2
-
性状 Solid
-
分子量 532.57
-
分子式 C27H29FN8O3
-
Color Light yellow to yellow
-
SMILES
FC1=C(C(NC)=O)C(NC2=C3C(NC=C3)=NC(NC4=CC5=C(CCN5C(CN(C)C)=O)C=C4OC)=N2)=CC=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. [Abstract]2021 Jul 16;12(1):4360. PMID: 34272384 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
-
ACS Chem Biol
A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family. [Abstract]2017 May 19;12(5):1245-1256. PMID: 28263556 -
Fundam Clin Pharmacol
Urolithin C increases glucose-induced ERK activation which contributes to insulin secretion. [Abstract]2020 Oct;34(5):571-580. PMID: 32083757 -
Biochem Biophys Res Commun
T2DM inhibition of endothelial miR-342-3p facilitates angiogenic dysfunction via repression of FGF11 signaling. [Abstract]2018 Sep 3;503(1):71-78. PMID: 29852165 -
-
溶剤 & 溶解度
体外:
DMSO : ≥ 100 mg/mL (187.77 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 3 mg/mL (5.63 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 3 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8777 mL | 9.3884 mL | 18.7769 mL | 46.9422 mL |
| 5 mM | 0.3755 mL | 1.8777 mL | 3.7554 mL | 9.3884 mL | |
| 10 mM | 0.1878 mL | 0.9388 mL | 1.8777 mL | 4.6942 mL | |
| 15 mM | 0.1252 mL | 0.6259 mL | 1.2518 mL | 3.1295 mL | |
| 20 mM | 0.0939 mL | 0.4694 mL | 0.9388 mL | 2.3471 mL | |
| 25 mM | 0.0751 mL | 0.3755 mL | 0.7511 mL | 1.8777 mL | |
| 30 mM | 0.0626 mL | 0.3129 mL | 0.6259 mL | 1.5647 mL | |
| 40 mM | 0.0469 mL | 0.2347 mL | 0.4694 mL | 1.1736 mL | |
| 50 mM | 0.0376 mL | 0.1878 mL | 0.3755 mL | 0.9388 mL | |
| 60 mM | 0.0313 mL | 0.1565 mL | 0.3129 mL | 0.7824 mL | |
| 80 mM | 0.0235 mL | 0.1174 mL | 0.2347 mL | 0.5868 mL | |
| 100 mM | 0.0188 mL | 0.0939 mL | 0.1878 mL | 0.4694 mL |
GSK1838705A 関連分類
HY-13020 関連分類
Powered by Bioz